A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia-Reference-Cited by-同舟云学术

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia

Published:2021-10 Issue:44 Volume:39 Page:6520-6528
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Fadlyana Eddy,Rusmil Kusnandi,Tarigan Rodman,Rahmadi Andri Reza,Prodjosoewojo Susantina,Sofiatin Yulia^ORCID,Khrisna Citra V.,Sari Rini Mulia,Setyaningsih Lilis,Surachman Fikrianti,Bachtiar Novilia Sjafri,Sukandar Hadyana^ORCID,Megantara Imam,Murad Chrysanti,Pangesti Krisna Nur A.,Setiawaty Vivi,Sudigdoadi Sunarjati,Hu Yaling,Gao Qiang,Kartasasmita Cissy B.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia;Ophinni;Acta Med Indones,2020

2. Coronavirus disease (COVID-19);WHO;Situation Report-132.,2020

3. Coronavirus Pandemic: A Serious Threat to Humanity;Gupta;J Health Manag,2020

4. A Novel Coronavirus from Patients with Pneumonia in China, 2019;Zhu;N Engl J Med,2020

5. Monitoring the COVID-19 epidemic in the context of widespread local transmission;García-Basteiro;Lancet Respir Med,2020

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil;The Brazilian Journal of Infectious Diseases;2024-09

2. Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation;International Journal of Infectious Diseases;2024-09

3. Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial;Nature Communications;2024-08-06

4. Safety, Immunogenicity, and Effectiveness of Chinese-Made COVID-19 Vaccines in the Real World: An Interim Report of a Living Systematic Review;Vaccines;2024-07-16

5. Long Term Follow Up of Antibody Titres Against SARS-CoV-2 6 Months After Primary Protein Subunit COVID-19 Vaccination (ZF2001) in Indonesian Adults and Older Adults;Open Access Journal of Clinical Trials;2024-07